With Merck veterans at the helm, Nektar launches subsidiary for pain compound

Nektar has been signaling for months that it planned to create a subsidiary to house analgesic NKTR-181, with a financial partner on board to fuel a commercial launch. Now that it has launched Inheris, the new wholly owned subsidiary,

Read the full 391 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE